A Study of Irinotecan Liposome in Advanced Pancreatic Cancer

Summary

To determine the safety and tolerability of irinotecan liposome in combination with oxaliplatin and 5-FU/LV in subjects with advanced pancreatic cancer who have not received prior systemic chemotherapy

Timeline

Start

2021-04-08

Primary completion

2024-06-28

Completion

2024-06-28

Publications

• Xu Q, Zhao X, Wang X, Zhu R, Cheng Y, Xia T, Wu H, Tian H, Sun Y, Zhang M, Gao C, Fu D, Wu X, Zheng T, Yin X, Chen Y, Chen X, Li Z, Chen R, Yang X, Wang H, Wang Q, Han X, Wu W. Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancreatic ductal adenocarcinoma. BMC Med. 2025 Jul 7;23(1):402. doi: 10.1186/s12916-025-04234-4.

Drugs

Indications